Jasmin Bektic

Jasmin Bektic

Auto-generated profile, based on publicly available information

Jasmin Bektic

Department of Urology, Medical University Innsbruck, Innsbruck, Austria

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 October 2013 in Prostate Cancer and Prostatic Diseases
Verified
Journal Article
Closed access
IHI Heidegger
I Heidegger
HKH Klocker
H Klocker
ESE Steiner
E Steiner
VSV Skradski
V Skradski
MLM Ladurner
M Ladurner
JBJ Bektic
J Bektic

9 January 2015 in Urologia Internationalis
Verified
Journal Article
Closed access
PDF file
DJDaniel Junker
Daniel Junker
GSGeorg Schäfer
Georg Schäfer
IHIsabel Heidegger
Isabel Heidegger
JBJasmin Bektic
Jasmin Bektic
MLMichael Ladurner
Michael Ladurner
FAFriedrich Aigner
Friedrich Aigner
Purpose: To evaluate multiparametric magnetic resonance imaging/transrectal ultrasound (mpMRI/TRUS) fusion targeted biopsy (TB) of the prostate for prostate cancer (PCa) diagnosis. Patients and Methods: From April 2013 to January 2014, 53 men were included in this prospective single-centre study. The degree of PCa suspicion from mpMRI findings was classified according to the PI-RADS scoring system. Of these, 50 patients underwent both an mpMRI/TRUS fusion TB and a 10-core systematic biopsy (SB) of the prostate and were eligible for analysis. Results: 225 targeted and 500 systematic cores were included in this study. PCa was histologically confirmed in 52.0% of patients (26/50), whereas TB revealed PCa in 46.0% (23/50) and SB in 36.0% (18/50). TB identified PCa in 16.0% of all patients (8/50) that were missed by SB. All told, the targeted core was 2.8 times more likely to be PCa-positive than the systematic core (29.3 vs. 10.4%). Conclusions: mpMRI/TRUS fusion TB of the prostate is safe, practicable and may improve PCa diagnosis using fewer biopsy cores compared to SB.

24 July 2003 in Molecular Carcinogenesis
Verified
Journal Article
Closed access
PDF file
IEIris E. Eder
Iris E. Eder
PHPetra Haag
Petra Haag
MBMark Basik
Mark Basik
SMSpyro Mousses
Spyro Mousses
JBJasmin Bektic
Jasmin Bektic
HKHelmut Klocker
Helmut Klocker

6 February 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
IHIsabel Heidegger
Isabel Heidegger
VSViktor Skradski
Viktor Skradski
ESEberhard Steiner
Eberhard Steiner
HKHelmut Klocker
Helmut Klocker
RPRenate Pichler
Renate Pichler
JBJasmin Bektic
Jasmin Bektic
Active surveillance (AS) is increasingly offered to patients with low risk prostate cancer. The present study was conducted to evaluate the risk of tumor under-grading and -staging for AS eligibility. Moreover, we analyzed possible biomarkers for predicting more unfavorable final tumor histology. 197 patients who underwent radical prostatectomy (RPE) but would have met the EAU (European Association of Urology) criteria for AS (PSA4–10 ng/ml), PSA density (6, extraprostatic extension and positive resection margin (R1) or correlated significantly with up-grading and/or extraprostatic extension in a multivariate model. Only R1 resections were predictable by combining intermediate PSA levels with two positive biopsy cores (p = 0.004). Sub-analyses showed that the number of biopsy cores (10 vs. 15 biopsy cores) had no influence on above mentioned results on predicting biopsy undergrading. Clinical courses of patients showed that 19.9% of patients had a biochemical relapse after RPE, among all of them were undergraded in the initial biopsy. In summary, this study shows that a multitude of patients fulfilling the criteria for AS are under-diagnosed. The use of preoperative PSA levels, PSA density and the number of positive cores were not predictable for undergrading in the present patient collective.

Verified
Journal Article
Open access
PDF file
IEIris E. Eder
Iris E. Eder
MEMartina Egger
Martina Egger
HNHannes Neuwirt
Hannes Neuwirt
CSChristof Seifarth
Christof Seifarth
DMDanilo Maddalo
Danilo Maddalo
HKHelmut Klocker
Helmut Klocker
Progression to castration resistance is a major problem in the treatment of advanced prostate cancer and is likely to be driven by activation of several molecular pathways, including androgen receptor (AR) and cyclic AMP-dependent protein kinase A (PKA). In this study, we examined the therapeutic efficacy of a combined inhibition of the AR and the regulatory subunit type Iα (RIα) of protein kinase A with second generation antisense oligonucleotides (ODNs) in androgen-sensitive LNCaP and castration-resistant LNCaPabl tumors in vivo. We found that targeting the AR alone inhibited LNCaP, as well as LNCaPabl tumors. Combined inhibition resulted in an improved response over single targeting and even a complete tumor remission in LNCaPabl. Western blot analysis revealed that both ODNs were effective in reducing their target proteins when administered alone or in combination. In addition, treatment with the ODNs was associated with an induction of apoptosis. Our data suggest that dual targeting of the AR and PKARIα is more effective in inhibiting LNCaP and LNCaPabl tumor growth than single treatment and may give a treatment benefit, especially in castration-resistant prostate cancers.

1 January 2014
Verified
Journal Article
Closed access
IHIsabel Heidegger
Isabel Heidegger
UNUdo Nagele
Udo Nagele
APAndreas Pircher
Andreas Pircher
Renate PichlerRenate Pichler
Renate Pichler
WHWolfgang Horninger
Wolfgang Horninger
JBJasmin Bektic
Jasmin Bektic